For overweight or obese individuals without diabetes, but with pre-existing cardiovascular disease, semaglutide (Ozempic, Wegovy) is not ...

Madrigal Pharmaceuticals' strong launch is confirmed with impressive sales in Q1 and Q2. Learn why MDGL stock could benefit ...

A Danish study has found that semaglutide, which controls blood glucose while ensuring weight loss, is associated with a ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...

More than two billion people worldwide live with overweight or obesity, conditions closely linked to an array of health ...